The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer

BACKGROUND: Multiple therapies exist for patients with metastatic castration-resistant prostate cancer (mCRPC). However, their improvement on progression-free survival (PFS) remains modest, potentially explained by tumor molecular heterogeneity. Several prognostic molecular biomarkers have been iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Crippa, Alessio, De Laere, Bram, Discacciati, Andrea, Larsson, Berit, Connor, Jason T., Gabriel, Erin E., Thellenberg, Camilla, Jänes, Elin, Enblad, Gunilla, Ullen, Anders, Hjälm-Eriksson, Marie, Oldenburg, Jan, Ost, Piet, Lindberg, Johan, Eklund, Martin, Grönberg, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318749/
https://www.ncbi.nlm.nih.gov/pubmed/32586393
http://dx.doi.org/10.1186/s13063-020-04515-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318749/
https://www.ncbi.nlm.nih.gov/pubmed/32586393
http://dx.doi.org/10.1186/s13063-020-04515-8

Ejemplares similares